160 related articles for article (PubMed ID: 26211902)
61. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
62. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
63. Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles.
Andrade LM; de Fátima Reis C; Maione-Silva L; Anjos JL; Alonso A; Serpa RC; Marreto RN; Lima EM; Taveira SF
Eur J Pharm Biopharm; 2014 Sep; 88(1):40-7. PubMed ID: 24816130
[TBL] [Abstract][Full Text] [Related]
64. Ellagic Acid Containing Nanostructured Lipid Carriers for Topical Application: A Preliminary Study.
Singh Hallan S; Sguizzato M; Pavoni G; Baldisserotto A; Drechsler M; Mariani P; Esposito E; Cortesi R
Molecules; 2020 Mar; 25(6):. PubMed ID: 32210106
[TBL] [Abstract][Full Text] [Related]
65. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application.
Pardeike J; Weber S; Haber T; Wagner J; Zarfl HP; Plank H; Zimmer A
Int J Pharm; 2011 Oct; 419(1-2):329-38. PubMed ID: 21839157
[TBL] [Abstract][Full Text] [Related]
66. Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid.
Silva EL; Carneiro G; Caetano PA; Goulart G; Ferreira Costa D; de Souza-Fagundes EM; Gomes DA; Ferreira LA
Expert Rev Anticancer Ther; 2015 Feb; 15(2):247-56. PubMed ID: 25611812
[TBL] [Abstract][Full Text] [Related]
67. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection.
Wang JJ; Liu KS; Sung KC; Tsai CY; Fang JY
Eur J Pharm Sci; 2009 Sep; 38(2):138-46. PubMed ID: 19591929
[TBL] [Abstract][Full Text] [Related]
68. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
Wang CF; Mäkilä EM; Kaasalainen MH; Liu D; Sarparanta MP; Airaksinen AJ; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Jan; 35(4):1257-66. PubMed ID: 24211082
[TBL] [Abstract][Full Text] [Related]
69. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers.
Luan J; Zhang D; Hao L; Qi L; Liu X; Guo H; Li C; Guo Y; Li T; Zhang Q; Zhai G
Colloids Surf B Biointerfaces; 2014 Feb; 114():255-60. PubMed ID: 24211416
[TBL] [Abstract][Full Text] [Related]
70. Superparamagnetic Iron Oxide-Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam.
Abbas H; Refai H; El Sayed N
J Pharm Sci; 2018 Aug; 107(8):2119-2127. PubMed ID: 29665379
[TBL] [Abstract][Full Text] [Related]
71. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
72. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Sui J; Cui Y; Cai H; Bian S; Xu Z; Zhou L; Sun Y; Liang J; Fan Y; Zhang X
Nanoscale; 2017 Feb; 9(8):2755-2767. PubMed ID: 28155940
[TBL] [Abstract][Full Text] [Related]
73. Preparation, characterization and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate.
Feng F; Zheng D; Zhang D; Duan C; Wang Y; Jia L; Wang F; Liu Y; Gao Q; Zhang Q
J Microencapsul; 2011; 28(4):280-5. PubMed ID: 21545318
[TBL] [Abstract][Full Text] [Related]
74. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Kim HY; Jung HU; Yoo SH; Yoo KS; Cheong J; Park BS; Yun I; Yoo YH
Cancer Lett; 2014 Dec; 355(1):61-9. PubMed ID: 25218348
[TBL] [Abstract][Full Text] [Related]
75. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
76. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori.
Seabra CL; Nunes C; Gomez-Lazaro M; Correia M; Machado JC; Gonçalves IC; Reis CA; Reis S; Martins MCL
Int J Pharm; 2017 Mar; 519(1-2):128-137. PubMed ID: 28088639
[TBL] [Abstract][Full Text] [Related]
77. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Mandpe L; Pokharkar V
Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
[TBL] [Abstract][Full Text] [Related]
78. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios.
Wen CJ; Yen TC; Al-Suwayeh SA; Chang HW; Fang JY
Nanomedicine (Lond); 2011 Nov; 6(9):1545-59. PubMed ID: 22077462
[TBL] [Abstract][Full Text] [Related]
79. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Teeranachaideekul V; Müller RH; Junyaprasert VB
Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
[TBL] [Abstract][Full Text] [Related]
80. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
